Moffitt Cancer Center: Clinical Trial 21179

COVID-19 UPDATE: Moffitt is offering third doses and vaccine booster shots. Learn More

Facebook

Twitter

Linkedin

Pinterest

Email

Clinical Trials Search

Back to Search Results

Clinical Trial 21179

Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT05050006

Phase: Phase II
Prinicipal Investigator: Sarnaik, Amod

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma

Summary

DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).

Objective

Primary Objectives: The primary objective is to evaluate the efficacy of ITIL-168 in advanced cutaneous melanoma. Secondary and Exploratory Objective(s): The secondary and exploratory objectives will further evaluate the safety and efficacy of ITIL-168, in addition to biomarker and health-related quality-of-life parameters.

Treatments

Therapies

Chemotherapy (NOS); Immunotherapy; Therapy (NOS)

Medications

IL-2 (Interleukin-2); ITIL-168 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

Inclusion Criteria

Histologically confirmed advanced (unresectable or metastatic) cutaneous melanoma.

Cohort 1: Disease that is relapsed after or refractory to at least 1 prior line of systemic therapy that must include a PD-1 inhibitor and, if positive for proto- oncogene BRAF V600 activating mutation, targeted therapy.

Cohort 2: Disease that is persistent after discontinuing PD-1 due to toxicity. Patients with a proto-oncogene BRAF V600 activating mutation must have progressed after targeted therapy.

Cohort 3: Disease that is stable (SD) after at least 4 doses of a PD-1 inhibitor. Patients with a proto-oncogene BRAF V600 activating mutation must have progressed after targeted therapy.

Medically suitable for surgical resection of tumor tissue

Following tumor resection for TIL harvest, will have, at minimum, 1 remaining measurable lesion as identified by CT or MRI per > Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Adequate bone marrow and organ function

Exclusion Criteria

History of another primary malignancy within the previous 3 years

Melanoma of uveal, acral, or mucosal origin

Previously received an allogeneic stem cell transplant or organ allograft

Previously received TIL or engineered cell therapy ( eg, CAR T-cell)

Significant cardiac disease

Stroke or transient ischemic attack within 12 months of enrollment

History of significant central nervous system (CNS) disorder

Symptomatic and/or untreated CNS metastases

History of significant autoimmune disease within 2 years prior to enrollment

Known history of severe, immediate hypersensitivity reaction attributed to cyclophosphamide, fludarabine, or IL-2.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.